Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Jazz Pharmaceuticals Plc's Business Segments
Jazz Pharmaceuticals Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
18
Largest Segment
Product and Services, Product Sales Net of Deductions
Total Revenue
$ 1,208
Regions Reported
2
Revenue Share by Reportable Segment - FY
- Product and Services, Product Sales Net of Deductions0%
- Sleep77.9%
- Xywav72.8%
- Oncology57.6%
- Epidiolex/Epidyolex44.8%
- Epilepsy44.8%
- Zepzelca17.1%
- Rylaze/Enrylaze16.8%
- Defitelio/defibrotide9.1%
- Product and Services, Royalties and Contract Revenue7.9%
- Modeyso7.4%
- High Sodium AG Oxybate Product Royalty Revenue6.5%
- Xyrem5.1%
- Vyxeos4.8%
- Other Countries4.1%
- Ziihera2.4%
- All other1.4%
- Other0.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product and Services, Product Sales Net of Deductions | $ 2,181 | - |
| Sleep | $ 941 | 77.9% |
| Xywav | $ 879 | 72.8% |
15 more segments available
Sign in to unlock the full Jazz Pharmaceuticals Plc dataset.
Revenue Share by Region - FY
- Europe8.6%
- Other Countries1.6%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Europe | $ 92 | 8.6% |
| Other Countries | $ 17 | 1.6% |
Revenue by Product & Service Category - FY
- Product and Services, Product Sales Net of Deductions95.9%
- Sleep41.1%
- Xywav38.2%
- Oncology31.2%
- Epilepsy23.4%
- Epidiolex/Epidyolex23.4%
- Rylaze/Enrylaze9.7%
- Zepzelca9.4%
- Defitelio/defibrotide4.4%
- Product and Services, Royalties and Contract Revenue4.1%
- Modeyso3.9%
- High Sodium AG Oxybate Product Royalty Revenue3.4%
- Xyrem2.9%
- Vyxeos2.5%
- Ziihera1.2%
- Other royalty and contract revenues0.7%
- Other Products0.3%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product and Services, Product Sales Net of Deductions | $ 1,025 | 95.9% |
| Sleep | $ 439 | 41.1% |
| Xywav | $ 408 | 38.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
14 more categories available
Sign in to unlock the full Jazz Pharmaceuticals Plc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Product and Services, Product Sales Net of Deductions0%
- Sleep77.9%
- Xywav72.8%
- Oncology57.6%
- Epidiolex/Epidyolex44.8%
- Epilepsy44.8%
- Zepzelca17.1%
- Rylaze/Enrylaze16.8%
- Defitelio/defibrotide9.1%
- Product and Services, Royalties and Contract Revenue7.9%
- Modeyso7.4%
- High Sodium AG Oxybate Product Royalty Revenue6.5%
- Xyrem5.1%
- Vyxeos4.8%
- Other Countries4.1%
- Ziihera2.4%
- All other1.4%
- Other0.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product and Services, Product Sales Net of Deductions | $ 2,181 | - |
| Sleep | $ 941 | 77.9% |
| Xywav | $ 879 | 72.8% |
15 more segments available
Sign in to unlock the full Jazz Pharmaceuticals Plc dataset.
Description of Jazz Pharmaceuticals Plc
Jazz Pharmaceuticals Plc is a bio-pharmaceutical company that primarily focuses on developing and commercializing innovative treatments for various medical conditions, including sleep disorders, oncology, and neurology. It was founded in 2003 and is headquartered in Dublin, Ireland.
The company's portfolio includes several marketed products, such as:
1. Xyrem: It is an FDA-approved medication for the treatment of the rare sleep disorder called cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy.
2. Erwinaze: It is a medication used in the treatment of acute lymphoblastic leukemia (ALL) to convert asparagine to aspartic acid, thereby starving tumor cells of asparagine.
3. Defitelio: It is a drug that is used in the treatment of rare, life-threatening, and rapidly progressing liver and lung conditions associated with stem cell transplant.
Jazz Pharmaceuticals has several drugs that are currently in the clinical trial phase for treating other medical conditions like resistant depression, fibromyalgia, and Parkinson's disease.
The company's revenue is generated primarily from the sale of its products, which are marketed and sold in the United States, Europe, and other regions. In 2020, Jazz Pharmaceuticals reported total corporate revenue of $2.3 billion.
Jazz Pharmaceuticals has a diverse team of approximately 2,200 employees worldwide who work together to develop, manufacture, and market its products. The company is committed to adhering to high ethical standards and ensures compliance with all legal and regulatory requirements.
Jazz Pharmaceuticals has received many awards and accolades for its efforts in the field of bio-pharmaceuticals, including the Pharma Marketing Award for its patient-focused marketing campaign for Xyrem. It has also been listed among the "Fastest Growing Companies" in Ireland and the United States.
Overall, Jazz Pharmaceuticals is a leading player in the bio-pharmaceutical industry with a focus on developing innovative treatments for various medical conditions. Its commitment to research, development, and high ethical standards has contributed to its success and growth over the years.
The company's portfolio includes several marketed products, such as:
1. Xyrem: It is an FDA-approved medication for the treatment of the rare sleep disorder called cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy.
2. Erwinaze: It is a medication used in the treatment of acute lymphoblastic leukemia (ALL) to convert asparagine to aspartic acid, thereby starving tumor cells of asparagine.
3. Defitelio: It is a drug that is used in the treatment of rare, life-threatening, and rapidly progressing liver and lung conditions associated with stem cell transplant.
Jazz Pharmaceuticals has several drugs that are currently in the clinical trial phase for treating other medical conditions like resistant depression, fibromyalgia, and Parkinson's disease.
The company's revenue is generated primarily from the sale of its products, which are marketed and sold in the United States, Europe, and other regions. In 2020, Jazz Pharmaceuticals reported total corporate revenue of $2.3 billion.
Jazz Pharmaceuticals has a diverse team of approximately 2,200 employees worldwide who work together to develop, manufacture, and market its products. The company is committed to adhering to high ethical standards and ensures compliance with all legal and regulatory requirements.
Jazz Pharmaceuticals has received many awards and accolades for its efforts in the field of bio-pharmaceuticals, including the Pharma Marketing Award for its patient-focused marketing campaign for Xyrem. It has also been listed among the "Fastest Growing Companies" in Ireland and the United States.
Overall, Jazz Pharmaceuticals is a leading player in the bio-pharmaceutical industry with a focus on developing innovative treatments for various medical conditions. Its commitment to research, development, and high ethical standards has contributed to its success and growth over the years.
Jazz Pharmaceuticals Plc is a prominent global biopharmaceutical company dedicated to the development, manufacture, and commercialization of specialty medications tailored to treat rare and serious medical conditions. The company operates through distinct segments, each addressing specific therapeutic areas, and offers a comprehensive portfolio of products and services designed to meet the needs of patients, healthcare providers, and the broader medical community.
Segments
1. Sleep and CNS Disorders:
- This segment is integral to Jazz’s mission, focusing on conditions affecting the central nervous system, particularly sleep disorders. The aim is to develop and bring to market innovative therapies that address the unique challenges associated with disorders such as narcolepsy, which disrupt normal sleep patterns and can severely affect quality of life.
2. Hematology/Oncology:
- This segment is committed to addressing the needs of patients battling various forms of cancer. Products developed in this category focus on hematological malignancies, including leukemia and lymphoma, as well as solid tumors. The goal is to provide effective treatment options that can improve patient outcomes in these serious conditions.
3. Neuroscience:
- In this segment, Jazz Pharmaceuticals concentrated its efforts on developing treatments for a variety of neurological disorders. This includes innovative therapies for pediatric sleep disorders, movement disorders, and other neurological conditions, emphasizing the need for specialized care in these complex areas.
Products
1. Xyrem (sodium oxybate) oral solution:
- Xyrem is a critical treatment option for patients suffering from narcolepsy with cataplexy. It works by reducing the frequency and severity of cataplexy attacks, which can significantly impair a patients daily functioning. Xyrem is recognized for its unique pharmacological profile and its ability to restore normal sleep patterns.
2. Sunosi (solriamfetol) tablets:
- This medication is designed to improve wakefulness in adults experiencing excessive sleepiness due to narcolepsy or obstructive sleep apnea. Sunosi’s formulation addresses a common yet debilitating symptom, thereby enhancing the quality of life for those affected.
3. Prialt (ziconotide) intrathecal solution:
- Prialt offers a non-opioid therapeutic alternative for managing severe chronic pain, particularly in patients who have not responded to conventional pain medications. It is specifically useful for patients with severe pain related to conditions such as cancer or AIDS, providing an innovative option in pain management.
4. Defitelio (defibrotide sodium) injection:
- As the first and only approved treatment for severe hepatic veno-occlusive disease (VOD), Defitelio plays a crucial role in the management of patients undergoing stem cell transplants. VOD is a serious condition that can arise in this patient population, making Defitelio an essential therapy for improving survival rates.
5. Erwinaze/Erwinase (asparaginase Erwinia chrysanthemi):
- This product is a vital component of multi-agent treatment regimens for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma. By targeting asparagine, a necessary amino acid, Erwinaze effectively starves leukemia cells, thus contributing to effective cancer treatment protocols.
Services
1. Medical Affairs:
- The Medical Affairs team plays a critical role in disseminating information about Jazz Pharmaceuticals’ products, ensuring that healthcare providers are equipped with the necessary knowledge to make informed treatment decisions in the context of the evolving healthcare landscape.
2. Regulatory Affairs:
- This department is essential for navigating the complex world of regulatory approvals. It manages the submission process for new drug applications (NDAs) and ensures compliance with regulatory standards, facilitating timely access to medications for patients.
3. Commercial Operations:
- The Commercial Operations team devises and implements strategies that maximize the reach and impact of Jazz’s products. This involves collaborative efforts with healthcare providers and other stakeholders to enhance patient access to critical therapies.
4. Manufacturing:
- Jazz Pharmaceuticals maintains rigorous manufacturing standards to ensure the quality and availability of its products. The company is committed to efficient production and distribution methods, ensuring that its medications are reliably available to healthcare providers and patients.
5. Clinical Research:
- Conducting clinical trials is fundamental to Jazz’s commitment to innovation. The Clinical Research team evaluates new therapies safety and efficacy across diverse patient populations, thus contributing to the ongoing development of new treatment options and improving current therapies.
Conclusion
Jazz Pharmaceuticals Plc represents a significant player in the biopharmaceutical landscape, focusing on addressing the urgent medical needs of patients with rare and serious conditions. Through dedicated segments, an innovative portfolio of products, and a comprehensive suite of services, Jazz strives to enhance patient outcomes and improve the quality of life for those affected by challenging health issues. Its commitment to research, development, and the commercialization of specialty medications continues to solidify its reputation as a leader in the industry.
Segments
1. Sleep and CNS Disorders:
- This segment is integral to Jazz’s mission, focusing on conditions affecting the central nervous system, particularly sleep disorders. The aim is to develop and bring to market innovative therapies that address the unique challenges associated with disorders such as narcolepsy, which disrupt normal sleep patterns and can severely affect quality of life.
2. Hematology/Oncology:
- This segment is committed to addressing the needs of patients battling various forms of cancer. Products developed in this category focus on hematological malignancies, including leukemia and lymphoma, as well as solid tumors. The goal is to provide effective treatment options that can improve patient outcomes in these serious conditions.
3. Neuroscience:
- In this segment, Jazz Pharmaceuticals concentrated its efforts on developing treatments for a variety of neurological disorders. This includes innovative therapies for pediatric sleep disorders, movement disorders, and other neurological conditions, emphasizing the need for specialized care in these complex areas.
Products
1. Xyrem (sodium oxybate) oral solution:
- Xyrem is a critical treatment option for patients suffering from narcolepsy with cataplexy. It works by reducing the frequency and severity of cataplexy attacks, which can significantly impair a patients daily functioning. Xyrem is recognized for its unique pharmacological profile and its ability to restore normal sleep patterns.
2. Sunosi (solriamfetol) tablets:
- This medication is designed to improve wakefulness in adults experiencing excessive sleepiness due to narcolepsy or obstructive sleep apnea. Sunosi’s formulation addresses a common yet debilitating symptom, thereby enhancing the quality of life for those affected.
3. Prialt (ziconotide) intrathecal solution:
- Prialt offers a non-opioid therapeutic alternative for managing severe chronic pain, particularly in patients who have not responded to conventional pain medications. It is specifically useful for patients with severe pain related to conditions such as cancer or AIDS, providing an innovative option in pain management.
4. Defitelio (defibrotide sodium) injection:
- As the first and only approved treatment for severe hepatic veno-occlusive disease (VOD), Defitelio plays a crucial role in the management of patients undergoing stem cell transplants. VOD is a serious condition that can arise in this patient population, making Defitelio an essential therapy for improving survival rates.
5. Erwinaze/Erwinase (asparaginase Erwinia chrysanthemi):
- This product is a vital component of multi-agent treatment regimens for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma. By targeting asparagine, a necessary amino acid, Erwinaze effectively starves leukemia cells, thus contributing to effective cancer treatment protocols.
Services
1. Medical Affairs:
- The Medical Affairs team plays a critical role in disseminating information about Jazz Pharmaceuticals’ products, ensuring that healthcare providers are equipped with the necessary knowledge to make informed treatment decisions in the context of the evolving healthcare landscape.
2. Regulatory Affairs:
- This department is essential for navigating the complex world of regulatory approvals. It manages the submission process for new drug applications (NDAs) and ensures compliance with regulatory standards, facilitating timely access to medications for patients.
3. Commercial Operations:
- The Commercial Operations team devises and implements strategies that maximize the reach and impact of Jazz’s products. This involves collaborative efforts with healthcare providers and other stakeholders to enhance patient access to critical therapies.
4. Manufacturing:
- Jazz Pharmaceuticals maintains rigorous manufacturing standards to ensure the quality and availability of its products. The company is committed to efficient production and distribution methods, ensuring that its medications are reliably available to healthcare providers and patients.
5. Clinical Research:
- Conducting clinical trials is fundamental to Jazz’s commitment to innovation. The Clinical Research team evaluates new therapies safety and efficacy across diverse patient populations, thus contributing to the ongoing development of new treatment options and improving current therapies.
Conclusion
Jazz Pharmaceuticals Plc represents a significant player in the biopharmaceutical landscape, focusing on addressing the urgent medical needs of patients with rare and serious conditions. Through dedicated segments, an innovative portfolio of products, and a comprehensive suite of services, Jazz strives to enhance patient outcomes and improve the quality of life for those affected by challenging health issues. Its commitment to research, development, and the commercialization of specialty medications continues to solidify its reputation as a leader in the industry.